JP2018504597A - 量子キャパシタンス感知 - Google Patents
量子キャパシタンス感知 Download PDFInfo
- Publication number
- JP2018504597A JP2018504597A JP2017536885A JP2017536885A JP2018504597A JP 2018504597 A JP2018504597 A JP 2018504597A JP 2017536885 A JP2017536885 A JP 2017536885A JP 2017536885 A JP2017536885 A JP 2017536885A JP 2018504597 A JP2018504597 A JP 2018504597A
- Authority
- JP
- Japan
- Prior art keywords
- sensing
- sensing method
- electrode
- measurements
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims abstract description 105
- 239000000758 substrate Substances 0.000 claims abstract description 45
- 238000000157 electrochemical-induced impedance spectroscopy Methods 0.000 claims abstract description 22
- 230000007613 environmental effect Effects 0.000 claims abstract description 13
- 238000005259 measurement Methods 0.000 claims description 76
- 239000000126 substance Substances 0.000 claims description 41
- 102000005962 receptors Human genes 0.000 claims description 39
- 108020003175 receptors Proteins 0.000 claims description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 36
- 229910021389 graphene Inorganic materials 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 229940000406 drug candidate Drugs 0.000 claims description 10
- 150000001720 carbohydrates Chemical group 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000002041 carbon nanotube Substances 0.000 claims description 4
- 229910021393 carbon nanotube Inorganic materials 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002847 impedance measurement Methods 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 239000002096 quantum dot Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108010038196 saccharide-binding proteins Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 7
- 238000007877 drug screening Methods 0.000 abstract description 5
- 239000000104 diagnostic biomarker Substances 0.000 abstract description 2
- 230000033772 system development Effects 0.000 abstract 1
- 241000894007 species Species 0.000 description 35
- 108010074051 C-Reactive Protein Proteins 0.000 description 18
- 102100032752 C-reactive protein Human genes 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 13
- 229910052737 gold Inorganic materials 0.000 description 13
- 239000010931 gold Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 239000010410 layer Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000013060 biological fluid Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 238000005498 polishing Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000002094 self assembled monolayer Substances 0.000 description 4
- 239000013545 self-assembled monolayer Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- -1 derivatives thereof Chemical compound 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910002804 graphite Inorganic materials 0.000 description 3
- 239000010439 graphite Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002052 molecular layer Substances 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 2
- 102100031786 Adiponectin Human genes 0.000 description 2
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100040407 Heat shock 70 kDa protein 1B Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001037968 Homo sapiens Heat shock 70 kDa protein 1B Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 102000019355 Synuclein Human genes 0.000 description 2
- 108050006783 Synuclein Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000005513 bias potential Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- JKOWKXHCMQEEQQ-UHFFFAOYSA-N cyclopenta-1,3-diene;11-cyclopenta-2,4-dien-1-ylundecane-1-thiol;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.SCCCCCCCCCCC[C-]1C=CC=C1 JKOWKXHCMQEEQQ-UHFFFAOYSA-N 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- CLSIFQGHPQDTHQ-DTWKUNHWSA-N (2s,3r)-2-[(4-carboxyphenyl)methyl]-3-hydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC1=CC=C(C(O)=O)C=C1 CLSIFQGHPQDTHQ-DTWKUNHWSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710203008 D-galactose-binding periplasmic protein Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 238000003775 Density Functional Theory Methods 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102100033299 Glia-derived nexin Human genes 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000757236 Homo sapiens Angiogenin Proteins 0.000 description 1
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
- 101710190483 Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 102100030874 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 101800000992 Melanocyte-stimulating hormone beta Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
- 108010005113 Serpin E2 Proteins 0.000 description 1
- 102000005821 Serpin E2 Human genes 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108050007673 Somatotropin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002593 electrical impedance tomography Methods 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108010090623 galactose binding protein Proteins 0.000 description 1
- 102000021529 galactose binding proteins Human genes 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 102000036202 glucose binding proteins Human genes 0.000 description 1
- 108091011004 glucose binding proteins Proteins 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 239000013461 intermediate chemical Substances 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- IGMQODZGDORXEN-UHFFFAOYSA-N pentadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCS IGMQODZGDORXEN-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/22—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
- G01N27/221—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance by investigating the dielectric properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/026—Dielectric impedance spectroscopy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/22—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
- G01N27/227—Sensors changing capacitance upon adsorption or absorption of fluid components, e.g. electrolyte-insulator-semiconductor sensors, MOS capacitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/27—Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R27/00—Arrangements for measuring resistance, reactance, impedance, or electric characteristics derived therefrom
- G01R27/02—Measuring real or complex resistance, reactance, impedance, or other two-pole characteristics derived therefrom, e.g. time constant
- G01R27/26—Measuring inductance or capacitance; Measuring quality factor, e.g. by using the resonance method; Measuring loss factor; Measuring dielectric constants ; Measuring impedance or related variables
- G01R27/2605—Measuring capacitance
-
- H01L29/1606—
-
- H01L31/115—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Power Engineering (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(i)酸化還元キャパシタンスCrは、実際には(キャパシタンスを通じて)その最適な電気化学的「半波電位」における、拘束された酸化還元基の電気化学的活性について報告する。
(ii)その他の電位では情報が全く収集できない。
(iii)フィルムの電気化学的活性が撹乱された場合、Crの測定値は変化する。特異的結合/認識事象以外の現象による撹乱(例:副反応/分解、溶媒の変化または電解質透過)は、必ずしも試験中の結合/認識事象と識別できるわけではない。
(A)印加電位の範囲にわたって実施される電気化学的インピーダンス分光法によって、印加電位に対するその電気化学的レスポンスが電極の局所環境における変化に鋭敏である感知エレメントによって官能基化された電極基板であって、感知エレメントが0.5から10nmのサイズを有する電極基板を含む作用電極を有する系の、複素インピーダンスZ*の複数の測定値を得ること;
(B)前記の複数のZ*測定値を、選択した周波数ωにおける複素キャパシタンスの実数成分C’および/または選択した周波数ωにおける複素キャパシタンスの虚数成分C”の複数の測定値に変換すること;
(C)(a)C’、(b)C”または(c)C’とC”の任意の組み合わせの測定値を、印可した電圧の関数として選択した周波数ωにおいて積分して積分測定値を得ること;および
(D)前記積分測定値から電極の局所環境を評価することを含む感知法。
−作用電極、対極およびポテンシオスタットを含む電気化学的分光器であって、前記作用電極が、印加電位に対するその電気化学的レスポンスが電極の局所環境の変化に鋭敏である感知エレメントで官能基化された電極基板であって、感知エレメントが0.5から10nmのサイズを有する電極基板を含む電気化学的分光器;
−前記電気化学的分光器から、印加電位の範囲にわたって、複数の複素インピーダンス測定値Z*を含む入力データを受信するよう構成された受信器;および
−(i)前記の複数のZ*測定値を、選択した周波数ωにおける複素キャパシタンスの実数成分C’および/または選択した周波数ωにおける複素キャパシタンスの虚数成分C”の複数の測定値に変換し、且つ(ii)選択した周波数ωにおける(a)C’、(b)C”、または(c)C’とC”の任意の組み合わせの前記測定値を印可電圧の関数として積分して積分値を得るよう構成されたプロセッサを含む装置。感知法は量子キャパシタンス感知法であってもよく、すなわち装置は量子キャパシタンス感知法における使用を目的としてもよい。
−電気化学的分光器から、印加電位の範囲にわたる複数の複素インピーダンス測定値Z*を含む入力データを得るステップ;
−前記の複数のZ*測定値を、選択した周波数ωにおける複素キャパシタンスの実数成分C’および/または選択した周波数ωにおける複素キャパシタンスの虚数成分C”の複数の測定値に変換するステップ;および
−選択した周波数ωにおける前記の(a)C’、(b)C”または(c)C’とC”の任意の組み合わせの測定値を、印可電圧の関数として積分して積分測定値を得るステップを実行させる記憶媒体。
電気化学的インピーダンス分光法(EIS)は、当業者に既知の技術である。一般に、変動交流電位を、作用電極と対極の間のバイアス(または直流)電位に印可する。一般に、EICは一定範囲の交流周波数ωにわたるスキャニングを包含する。入力シグナル(典型的には変動電位)の出力シグナル(典型的には変動電流)に対する比率よりインピーダンスを算出することができる。一般的に、入力シグナルと出力シグナルの間には位相差があるので、インピーダンスは実数部分(時にZ’と呼ばれる)と虚数部分(時にZ”と呼ばれる)を有する複素関数Z*とみなすことができる。
作用電極は、感知エレメントで官能基化された電極基板を含む。
本発明の原理は幅広く適用することができる。具体的には、物理的物質または物理的物質以外の環境パラメータのいずれも感知することができる。ほとんどあらゆる物質または環境パラメータは、その物質の量またはパラメータの変化が作用電極の局所環境の変化をもたらし、且つそれゆえに感知エレメントと電極基板の間の電子分布の変化をもたらすのであれば、これを感知することができる。したがって、作用電極はそのために用いることになる意図する感知法について設計することができる。
1つの実施形態においては、方法は化学物質、すなわち化学化合物または化学化合物群を感知するための方法である。この実施形態においては、ステップ(A)において作用電極が物質を含みうる担体媒体と接触し、また印加電位に対する感知エレメントの電気化学的レスポンスは前記物質の存在に対して鋭敏である。担体媒体が物質を含有する場合、特定の積分測定値が得られる。担体媒体が物質を含有しない場合、積分測定値は異なる。同様に、担体媒体中の物質の濃度が変化するにつれて積分測定値の変化が発生する。
物質は、標的種、すなわち任意選択的に1つまたはそれ以上の他の非標的種と共に、担体媒体中に存在することもあれば存在しないこともあり、且つユーザーが検出/感知することを所望する種とすることできる。最も典型的には、方法は前記担体媒体中の前記標的種の濃度を判定するための方法である。
本発明の方法は、グリコアレイを包含する用途においても使用することができる。グリコアレイは、各アレイ単位が特異的な炭水化物部分(他のアレイ単位における炭水化物部分と異なる)を含むアレイである。本発明の文脈においては、アレイは複数の別個にアドレス指定できる電気化学的系を含み、それぞれの作用電極は炭水化物部分である受容体部分によって官能基化される。たとえば、炭水化物部分のアレイは、ヒトなどの生物のグリコームまたはグリコームの一部を構成しうる。
本発明のための方法の他の用途は、薬剤スクリーニングおよび創薬の分野にある。薬剤スクリーニングを目的としたアレイによる既知の系においては、各アレイ単位が、薬剤候補がそこに結合すれば薬剤候補が治療上対象となりうることが明確に示される、到達可能な受容体部分を含む。たとえば、タキソール−チューブリンモデルに基づく既知のスクリーニング法がある。このモデルにおいては、既知の抗癌剤タキソールとチューブリンプロテシンとの相互作用活性を、新規薬剤候補と比較する参照として用いる。
さらなる実施形態においては、方法は電極の局所環境における環境パラメータの変化を感知するための方法である。そのような環境パラメータの例は、局所環境の温度、局所環境の光度(例:可視光強度、またはその代わりまたはそれに加えて紫外線強度)および局所環境における湿度を含む。
本発明は、典型的には本発明の感知法である、感知法における使用を目的とした装置も提供する。この装置は、その作用電極が感知エレメントによって官能基化された電気化学分光器、すなわち本発明の方法を実施するために特に適合された電気化学分光器を含む。作用電極は本願に記載される。
(図4の)各パラメータ、すなわち量子キャパシタンス
「RR」を標的濃度にわたって収集することにより、図4に示すようにパラメータのそれぞれに対して分析曲線をプロットすることが可能であった。
Claims (20)
- 感知法であって:
(A)印加電位の範囲にわたって実施される電気化学的インピーダンス分光法によって、前記印加電位に対するその電気化学的レスポンスが電極の局所環境における変化に鋭敏である感知エレメントによって官能基化された電極基板であって、前記感知エレメントが0.5から10nmのサイズを有する前記電極基板を含む作用電極を有する系の、複素インピーダンスZ*の複数の測定値を得ること;
(B)前記の複数のZ*測定値を、選択した周波数ωにおける複素キャパシタンスの実数成分C’および/または選択した周波数ωにおける複素キャパシタンスの虚数成分C”の複数の測定値に変換すること;
(C)前記の(a)C’、(b)C”または(c)C’とC”の任意の組み合わせの測定値を、印可電圧の関数として前記の選択した周波数ωにおいて積分して積分測定値を得ること;および
(D)前記積分測定値から前記の電極の局所環境を評価することを含む前記感知法。 - 請求項1に記載の感知法であって、ステップ(A)において、前記の、印加電位の範囲にわたって実施される電気化学的インピーダンス分光法により、前記複素インピーダンスの複数の測定値を得ることが、異なる印加電位における少なくとも5つの前記複素インピーダンスの測定値を得ることを含む前記感知法。
- 請求項1または2に記載の感知法であって、ステップ(D)における前記の評価することが前記積分測定値を前記の電極の局所環境が既知である条件下でステップ(A)、(B)および(C)を実施することにより得られる1つまたはそれ以上の参照値と比較することによって実施される前記感知法。
- 前述の請求項のうちいずれか1つに記載の感知法であって、化学物質を感知するための方法であって、且つ:
−ステップ(A)において前記作用電極が前記物質を含みうる媒体担体と接触し;
−前記印加電位に対する前記感知エレメントの前記電気化学的レスポンスが前記物質の存在に鋭敏であり;且つ
−ステップ(D)において前記の評価することが前記化学物質が前記担体媒体中に存在するか感知することを含む前記感知法。 - 請求項4に記載の感知法であって:
−前記作用電極が前記物質と結合することの可能な受容体部分を含み;且つ
−前記印加電位に対する前記感知エレメントの前記電気化学的レスポンスが前記物質の前記受容体部分と結合することに鋭敏である前記感知法。 - 請求項5に記載の感知法であって、前記物質がそこに前記受容体部分が特異的に結合することが可能な標的種であり、且つ前記方法が前記担体媒体中の前記標的種の濃度を測定するための方法である前記感知法。
- 請求項6に記載の感知法であって、前記標的種がCRPタンパク質、インスリンおよび神経変性、癌、心筋梗塞、糖尿病および一般的外傷のうち1つまたはそれ以上のマーカーからなる群から選択される前記感知法。
- 請求項5に記載の感知法であって、前記物質がレクチンタンパク質、糖酵素および炭水化物結合抗体から選択され、且つ前記受容体部分が炭水化物部分である前記感知法。
- 請求項8に記載の感知法であって、前記作用電極がそれぞれが異なる炭水化物部分によって官能基化された複数の作用電極を含むグリコアレイの一部を形成する前記感知法。
- 請求項5に記載の感知法であって、前記物質が薬剤候補であり、且つ前記受容体部分が参照薬剤と結合することの可能な部分である前記感知法。
- 請求項10に記載の感知法であって、前記作用電極がそれぞれが前記受容体部分で官能基化された複数の作用電極を含むアレイの一部を形成し、これにより前記アレイが複数の薬剤候補の同時スクリーニングにおける使用に適している前記感知法。
- 請求項1から3のうちいずれか1つに記載の感知法であって、温度、光度、および湿度から選択される環境パラメータの変化を感知するための方法である感知法。
- 前述の請求項のうちいずれか1つに記載の感知法であって、前記感知エレメントが1つまたはそれ以上の酸化還元活性種、分子フィルム、ナノ粒子、グラフェン、カーボンナノチューブまたは量子ドットを含む前記感知法。
- 前述の請求項のうちいずれか1つに記載の感知法であって、前記作用電極が酸化還元活性種によって官能基化されない前記感知法。
- 請求項5から14のいずれか1つに記載の感知法であって、前記の物質と結合することの可能な前記の受容体部分が抗体または抗体フラグメントを含む前記感知法。
- 前述の請求項のうちいずれか1つに記載の感知法であって、前記感知エレメントがグラフェンを含む前記感知法。
- 感知法のために用いる装置であって、当該装置が:
−作用電極、対極およびポテンシオスタットを含む電気化学的分光器であって、前記作用電極が印加電位に対するその電気化学的レスポンスが前記の電極の局所環境の変化に鋭敏である感知エレメントによって官能基化された電極基板であって、前記感知エレメントが0.5から10nmのサイズを有する前記電極基板を含む電気化学的分光器;
−前記電気化学的分光器から、印加電位の範囲にわたって、複数の複素インピーダンス測定値Z*を含む入力データを受信するよう構成された受信器;および
−(i)前記の複数のZ*測定値を、選択した周波数ωにおける複素キャパシタンスの実数成分C’および/または選択した周波数ωにおける複素キャパシタンスの虚数成分C”の複数の測定値に変換し、且つ(ii)前記の選択した周波数ωにおける、前記の(a)C’、(b)C”、または(c)C’とC”の任意の組み合わせの前記測定値を印可電圧の関数として積分して積分測定値を得るよう構成されたプロセッサを含む前記装置。 - 請求項17に記載の装置であって、前記積分測定値から生成されたデータを出力するよう構成された出力ユニットをさらに含む前記装置。
- 請求項1から16のいずれか1つに記載の感知法、または請求項17または請求項18に記載の装置であって、前記感知法が量子キャパシタンス感知法である前記感知法または装置。
- コンピュータまたはコンピュータのネットワークによる実行のためのコンピュータ読取り可能コードを記憶する記憶媒体であって、コードが、実行される際に、コンピュータまたはコンピュータのネットワークに:
−電気化学的分光器から、印加電位の範囲にわたる複数の複素インピーダンスZ*測定値を含む入力データを得るステップ;
−前記の複数のZ*測定値を、選択した周波数ωにおける複素キャパシタンスの実数成分C’および/または選択した周波数ωにおける複素キャパシタンスの虚数成分C”の複数の測定値に変換するステップ;および
−前記の選択した周波数ωにおける、前記の(a)C’、(b)C”または(c)C’とC”の任意の組み合わせの測定値を、印可電圧の関数として積分して積分測定値を得るステップを実行させる記憶媒体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1501232.1A GB201501232D0 (en) | 2015-01-26 | 2015-01-26 | Quantum capacitance sensing |
GB1501232.1 | 2015-01-26 | ||
PCT/GB2016/050162 WO2016120606A1 (en) | 2015-01-26 | 2016-01-26 | Quantum capacitance sensing |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018504597A true JP2018504597A (ja) | 2018-02-15 |
JP2018504597A5 JP2018504597A5 (ja) | 2019-04-04 |
JP6543346B2 JP6543346B2 (ja) | 2019-07-10 |
Family
ID=52673910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017536885A Active JP6543346B2 (ja) | 2015-01-26 | 2016-01-26 | 量子キャパシタンス感知 |
Country Status (17)
Country | Link |
---|---|
US (1) | US10309918B2 (ja) |
EP (1) | EP3250911B1 (ja) |
JP (1) | JP6543346B2 (ja) |
KR (1) | KR20180008375A (ja) |
CN (1) | CN107438763B (ja) |
AU (1) | AU2016211061B2 (ja) |
BR (1) | BR112017014761B1 (ja) |
CA (1) | CA2973003C (ja) |
DK (1) | DK3250911T3 (ja) |
ES (1) | ES2731470T3 (ja) |
GB (1) | GB201501232D0 (ja) |
IL (1) | IL253289B (ja) |
MX (1) | MX2017008867A (ja) |
RU (1) | RU2701751C2 (ja) |
SG (1) | SG11201705558TA (ja) |
TR (1) | TR201907802T4 (ja) |
WO (1) | WO2016120606A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210020741A (ko) * | 2019-08-16 | 2021-02-24 | 연세대학교 산학협력단 | 멀티 입력 기반의 저항 변화 메모리 소자 |
WO2021241277A1 (ja) * | 2020-05-29 | 2021-12-02 | 国立大学法人広島大学 | インスリンの検出方法および検出キット |
US11437570B2 (en) | 2019-08-16 | 2022-09-06 | Yonsei University, University—Industry Foundation (UIF) | Resistive switching memory device based on multi-inputs |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102094241B1 (ko) * | 2018-04-17 | 2020-03-27 | 고려대학교산학협력단 | 혈액 샘플 내 피브리노겐 농도 측정 방법 및 이를 위한 나노입자 |
US12111278B2 (en) * | 2019-01-31 | 2024-10-08 | The Board Of Trustees Of The University Of Alabama | Portable impedance based chemical sensor |
CN115605755A (zh) * | 2020-01-17 | 2023-01-13 | 石墨烯-Dx 股份有限公司(Us) | 收集点石墨烯基毒理学传感器 |
US20230081940A1 (en) | 2020-01-29 | 2023-03-16 | Oxford University Innovation Limited | Analyte detection with redox active polymer-coated electrode |
CN112816790B (zh) * | 2021-02-02 | 2021-11-19 | 北京大学 | 一种量子电容测量系统及其测量方法 |
GB202115704D0 (en) | 2021-11-02 | 2021-12-15 | Univ Oxford Innovation Ltd | Redox capacitance sensing of particles under flow |
WO2023092210A1 (pt) * | 2021-11-26 | 2023-06-01 | Universidade Estadual Paulista Julio De Mesquita Filho | Método e dispositivo de amplificação de sinal transdutor para ensaios capacitivos |
WO2023137534A1 (pt) * | 2022-01-13 | 2023-07-27 | Universidade Estadual Paulista Julio De Mesquita Filho | Transdutor modificado, mecanismo de transdução e método de detecção e/ou quantificação de espécies de interesse analítico com transdutor modificado |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1427821B1 (en) * | 2001-08-20 | 2007-06-20 | Regenesis Bioremediation Products | Biosensor for small molecule analytes |
US7022287B2 (en) * | 2002-05-08 | 2006-04-04 | Sandia National Laboratories | Single particle electrochemical sensors and methods of utilization |
WO2006052891A1 (en) * | 2004-11-09 | 2006-05-18 | The Regents Of The University Of California | Analyte identification using electronic devices |
CN101213461B (zh) * | 2005-06-03 | 2013-01-02 | 辛纳普蒂克斯公司 | 使用sigma-delta测量技术检测电容的方法和系统 |
CN102753965B (zh) | 2009-12-09 | 2016-01-13 | Iti苏格兰有限公司 | 检测分析物 |
WO2012009322A1 (en) | 2010-07-12 | 2012-01-19 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Methods and device for tuning multiplexed markers for disease assay |
US9513244B2 (en) | 2011-04-14 | 2016-12-06 | Regents Of The University Of Minnesota | Ultra-compact, passive, varactor-based wireless sensor using quantum capacitance effect in graphene |
CN102382758B (zh) * | 2011-10-14 | 2014-12-17 | 杭州捷诺飞生物科技有限公司 | 基于细胞打印和多参数传感阵列集成技术的三维细胞芯片 |
US20130102031A1 (en) * | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
US20130319880A1 (en) * | 2012-06-04 | 2013-12-05 | Ching-Chou Wu | Impedimetric Biosensor System With Improved Sensing Efficiency |
GB201212528D0 (en) * | 2012-07-13 | 2012-08-29 | Isis Innovation | Assay |
US9423234B2 (en) * | 2012-11-05 | 2016-08-23 | The Regents Of The University Of California | Mechanical phenotyping of single cells: high throughput quantitative detection and sorting |
US20140342442A1 (en) * | 2013-05-15 | 2014-11-20 | Bioo Scientific Corporation | Touchscreen device and methods for use in detection of microrna |
GB201314402D0 (en) | 2013-08-12 | 2013-09-25 | Isis Innovation | Capacitance Spectroscopic Method and Electrode |
CN103913493B (zh) * | 2014-04-24 | 2015-07-08 | 青岛大学 | Keggin型杂多酸功能化石墨烯负载铜纳米粒子修饰电极及应用 |
-
2015
- 2015-01-26 GB GBGB1501232.1A patent/GB201501232D0/en not_active Ceased
-
2016
- 2016-01-26 TR TR2019/07802T patent/TR201907802T4/tr unknown
- 2016-01-26 KR KR1020177018888A patent/KR20180008375A/ko unknown
- 2016-01-26 JP JP2017536885A patent/JP6543346B2/ja active Active
- 2016-01-26 MX MX2017008867A patent/MX2017008867A/es active IP Right Grant
- 2016-01-26 WO PCT/GB2016/050162 patent/WO2016120606A1/en active Application Filing
- 2016-01-26 EP EP16701879.5A patent/EP3250911B1/en active Active
- 2016-01-26 RU RU2017123574A patent/RU2701751C2/ru active
- 2016-01-26 AU AU2016211061A patent/AU2016211061B2/en active Active
- 2016-01-26 ES ES16701879T patent/ES2731470T3/es active Active
- 2016-01-26 BR BR112017014761-0A patent/BR112017014761B1/pt active IP Right Grant
- 2016-01-26 SG SG11201705558TA patent/SG11201705558TA/en unknown
- 2016-01-26 CN CN201680005803.3A patent/CN107438763B/zh active Active
- 2016-01-26 DK DK16701879.5T patent/DK3250911T3/da active
- 2016-01-26 CA CA2973003A patent/CA2973003C/en active Active
-
2017
- 2017-07-03 IL IL253289A patent/IL253289B/en active IP Right Grant
- 2017-07-06 US US15/643,208 patent/US10309918B2/en active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210020741A (ko) * | 2019-08-16 | 2021-02-24 | 연세대학교 산학협력단 | 멀티 입력 기반의 저항 변화 메모리 소자 |
KR102294284B1 (ko) | 2019-08-16 | 2021-08-26 | 연세대학교 산학협력단 | 멀티 입력 기반의 저항 변화 메모리 소자 |
US11437570B2 (en) | 2019-08-16 | 2022-09-06 | Yonsei University, University—Industry Foundation (UIF) | Resistive switching memory device based on multi-inputs |
WO2021241277A1 (ja) * | 2020-05-29 | 2021-12-02 | 国立大学法人広島大学 | インスリンの検出方法および検出キット |
JP2021189040A (ja) * | 2020-05-29 | 2021-12-13 | 国立大学法人広島大学 | インスリンの検出方法および検出キット |
JP7479627B2 (ja) | 2020-05-29 | 2024-05-09 | 国立大学法人広島大学 | インスリンの検出方法および検出キット |
Also Published As
Publication number | Publication date |
---|---|
BR112017014761B1 (pt) | 2021-06-08 |
IL253289A0 (en) | 2017-09-28 |
CA2973003A1 (en) | 2016-08-04 |
GB201501232D0 (en) | 2015-03-11 |
IL253289B (en) | 2020-10-29 |
JP6543346B2 (ja) | 2019-07-10 |
MX2017008867A (es) | 2018-03-28 |
RU2017123574A3 (ja) | 2019-07-25 |
SG11201705558TA (en) | 2017-08-30 |
KR20180008375A (ko) | 2018-01-24 |
DK3250911T3 (da) | 2019-07-29 |
TR201907802T4 (tr) | 2019-06-21 |
EP3250911B1 (en) | 2019-05-22 |
RU2701751C2 (ru) | 2019-10-01 |
CA2973003C (en) | 2021-07-06 |
CN107438763A (zh) | 2017-12-05 |
WO2016120606A1 (en) | 2016-08-04 |
RU2017123574A (ru) | 2019-02-28 |
CN107438763B (zh) | 2020-03-03 |
ES2731470T3 (es) | 2019-11-15 |
BR112017014761A2 (pt) | 2018-01-16 |
AU2016211061A1 (en) | 2017-07-27 |
EP3250911A1 (en) | 2017-12-06 |
US10309918B2 (en) | 2019-06-04 |
US20170370867A1 (en) | 2017-12-28 |
AU2016211061B2 (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6543346B2 (ja) | 量子キャパシタンス感知 | |
Kesler et al. | Going beyond the Debye length: overcoming charge screening limitations in next-generation bioelectronic sensors | |
US10830727B2 (en) | Electrode and use thereof | |
Kuo et al. | Improving sensitivity of a miniaturized label-free electrochemical biosensor using zigzag electrodes | |
Patil et al. | Immittance electroanalysis in diagnostics | |
US20210132050A1 (en) | Peptide-comprising electrode | |
Bedatty Fernandes et al. | Optimized diagnostic assays based on redox tagged bioreceptive interfaces | |
Xu et al. | Graphene oxide interfaces in serum based autoantibody quantification | |
Juskova et al. | Fabrication and characterization of solid mercury amalgam electrodes for protein analysis | |
US10545113B2 (en) | Electrochemical detection method | |
Burcu Aydın | A label-free and sensitive impedimetric immunosensor for TNF α biomarker detection based on epoxysilane-modified disposable ITO-PET electrode | |
US10564154B2 (en) | Capacitance spectroscopic method and electrode | |
US20230081940A1 (en) | Analyte detection with redox active polymer-coated electrode | |
Barsan et al. | Immobilized antibodies on mercaptophenylboronic acid monolayers for dual-strategy detection of 20s proteasome | |
Teke et al. | A novel biosensing system using biological receptor for analysis of vascular endothelial growth factor | |
Arı et al. | A novel electrochemical approach to biosensing applications: Quartz tuning forks as working electrodes for immunosensors | |
Asav et al. | Quantitative analysis of a promising cancer biomarker, calretinin, by a biosensing system based on simple and effective immobilization process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190123 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190123 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190225 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190411 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190604 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190614 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6543346 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |